PDL BioPharma has announced a series of new appointment recently.
Mark McCamish has joined the company as senior vice president and chief medical officer.
He will oversee all clinical development functions and programmes, including regulatory affairs, safety, clinical development, and data management.
McCamish served as chief medical officer and vice president of clinical development at Perlegen Sciences.
The contract manufacturing organisation (CMO) also announced the promotion of Richard Murray to executive vice president and chief scientific officer.
Murray joined PDL as vice president of research in 2003.
In his new roles, he will continue to oversee the firm's antibody discovery, manufacturing and preclinical activities, in addition to participating as a board member.
Meanwhile, clinical trial management firm Synexus has appointed Alan Boyce as chief operating officer, with responsibility for the company's operations in Poland, Hungary, Bulgaria, India, South Africa and the UK.
Boyce joins from Kendle where he was vice president of operations, Europe, Middle East and Africa.
Kendle has also announced senior executive appointments to strengthen its global clinical development operations.
The company has selected Martha Feller to be senior vice president of global clinical development.
The CRO has also announced the appointments of Ubavka Denoble and Judith Swilley to vice president and senior director of global clinical development, North America, respectively.
In other news, PharmaNet Development Group has announced that Johane Boucher-Champagne, executive vice president, early clinical development of PharmaNet Development Group, has been appointed president and chief executive officer of Anapharm , a subsidiary of the CRO, effective 18 March.
Separately, Pharmanet's president and CEO, Jeffrey McMullen, was elected Chair of the Association of Clinical Research Organisations (ACRO), which represents the clinical outsourcing industry in the US and worldwide, recently elected new officers.
In addition, David Spaight, president of MDS Pharma will serve as Chair-Elect of the association.
Contract manufacturer MDS has named Douglas Prince as executive vice president of finance and chief financial officer, effective 12 March.
He replaces Jim Garner, who will leave the company at the end of April.
In the UK, Chiltern International said that Stuart Young has joined the CRO as global head of clinical monitoring.
Prior to that, Young held senior management positions at Wyeth and Charles River Laboratories.
And finally, bioprocessing services firm Laureate Pharma announced yesterday the election of Tracy Ken Tsuetaki as new non-executive Chairman of its board of directors.